跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
REZUROCK - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
REZUROCK
Authorized
STANDARD
REZUROCK
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ef3f2a03c18007fe
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
ef3f2a03c18007fe
Drug Approval Canada Name
REZUROCK
Product Name
REZUROCK
Status
Marketed
Status Date
2023-03-08
Original Market Date
2023-03-08
Din
02526115
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
92:92.00
Atc Original
L04AA48 BELUMOSUDIL
Atc Name
l 04 aa 48
Aig Number
0163502001
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
BELUMOSUDIL (BELUMOSUDIL MESYLATE)
200 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ef3f2a03c18007fe
Type
Standard
Back to Health Canada Approvals